Compare BCG & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | BCG | MDXH |
|---|---|---|
| Founded | 2016 | 2003 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.6M | 18.5M |
| IPO Year | 2025 | 2021 |
| Metric | BCG | MDXH |
|---|---|---|
| Price | $1.07 | $0.19 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $1.13 |
| AVG Volume (30 Days) | 16.2K | ★ 1.3M |
| Earning Date | 11-12-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 112.50 | N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $187,144,000.00 | N/A |
| Revenue This Year | N/A | $5.10 |
| Revenue Next Year | N/A | $13.22 |
| P/E Ratio | $13.50 | ★ N/A |
| Revenue Growth | ★ 10.80 | N/A |
| 52 Week Low | $0.95 | $0.17 |
| 52 Week High | $3.44 | $5.33 |
| Indicator | BCG | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 46.11 | 23.19 |
| Support Level | $0.95 | N/A |
| Resistance Level | $1.67 | $0.66 |
| Average True Range (ATR) | 0.04 | 0.05 |
| MACD | 0.02 | -0.04 |
| Stochastic Oscillator | 75.06 | 2.27 |
Binah Capital Group Inc formerly Wentworth Management Services LLC is a holding company that acquires and manages businesses in the wealth management industry. The company specializes in consolidating independent broker-dealers to capture economies of scale needed to service financial advisors in today's technology-enabled regulatory environment. Wentworth's core philosophy focuses on building long-term, productive relationships with its advisor base.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.